Mixed Aspergillosis and Mucormycosis Infections in Patients with COVID-19 : Case Series and Literature Review
© 2024. The Author(s), under exclusive licence to Springer Nature B.V..
BACKGROUND: Mucormycosis and aspergillosis are angioinvasive infections mainly occurring in immunocompromised patients. However, mixed infection with mucormycosis and aspergillosis in post-COVID-19 patients is rare. In this report, we will report four cases and comprehensively review the published literature on COVID-19 associated mixed infection of aspergillosis and mucormycosis.
METHOD: Besides four of our cases, we searched for published articles using PubMed/MEDLINE, Scopus, and Web of Science databases from the beginning of 2020 until October 2023.
RESULT: During the COVID-19 pandemic, we analyzed 52 cases (4 from our research and 48 from other studies). The most common underlying disease (59.6%) was diabetes mellitus. However, 19.2% of COVID-19 patients had no underlying condition. Interestingly, rhino-orbital-cerebral mucormycosis featured prominently in India and Iran, while other countries primarily reported a higher prevalence of pulmonary cases.
CONCLUSION: In conclusion, this study highlights the presence of mixed aspergillosis and mucormycosis in COVID-19 patients who previously had common underlying diseases or even a healthy immune system. Therefore, managing COVID-19 patients should involve screening serum and respiratory samples using biomarkers to detect superinfections.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:189 |
---|---|
Enthalten in: |
Mycopathologia - 189(2024), 1 vom: 17. Jan., Seite 10 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Sasani, Elahe [VerfasserIn] |
---|
Links: |
---|
Themen: |
Aspergillosis |
---|
Anmerkungen: |
Date Completed 18.01.2024 Date Revised 29.02.2024 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1007/s11046-023-00808-z |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM367219638 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM367219638 | ||
003 | DE-627 | ||
005 | 20240301232337.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240117s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s11046-023-00808-z |2 doi | |
028 | 5 | 2 | |a pubmed24n1313.xml |
035 | |a (DE-627)NLM367219638 | ||
035 | |a (NLM)38231407 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Sasani, Elahe |e verfasserin |4 aut | |
245 | 1 | 0 | |a Mixed Aspergillosis and Mucormycosis Infections in Patients with COVID-19 |b Case Series and Literature Review |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 18.01.2024 | ||
500 | |a Date Revised 29.02.2024 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2024. The Author(s), under exclusive licence to Springer Nature B.V. | ||
520 | |a BACKGROUND: Mucormycosis and aspergillosis are angioinvasive infections mainly occurring in immunocompromised patients. However, mixed infection with mucormycosis and aspergillosis in post-COVID-19 patients is rare. In this report, we will report four cases and comprehensively review the published literature on COVID-19 associated mixed infection of aspergillosis and mucormycosis | ||
520 | |a METHOD: Besides four of our cases, we searched for published articles using PubMed/MEDLINE, Scopus, and Web of Science databases from the beginning of 2020 until October 2023 | ||
520 | |a RESULT: During the COVID-19 pandemic, we analyzed 52 cases (4 from our research and 48 from other studies). The most common underlying disease (59.6%) was diabetes mellitus. However, 19.2% of COVID-19 patients had no underlying condition. Interestingly, rhino-orbital-cerebral mucormycosis featured prominently in India and Iran, while other countries primarily reported a higher prevalence of pulmonary cases | ||
520 | |a CONCLUSION: In conclusion, this study highlights the presence of mixed aspergillosis and mucormycosis in COVID-19 patients who previously had common underlying diseases or even a healthy immune system. Therefore, managing COVID-19 patients should involve screening serum and respiratory samples using biomarkers to detect superinfections | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a Aspergillosis | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a Co-infection | |
650 | 4 | |a Mucormycosis | |
700 | 1 | |a Pakdel, Farzad |e verfasserin |4 aut | |
700 | 1 | |a Khodavaisy, Sadegh |e verfasserin |4 aut | |
700 | 1 | |a Salehi, Mohammadreza |e verfasserin |4 aut | |
700 | 1 | |a Salami, Amir |e verfasserin |4 aut | |
700 | 1 | |a Sohrabi, Marjan |e verfasserin |4 aut | |
700 | 1 | |a Aminishakiba, Pouyan |e verfasserin |4 aut | |
700 | 1 | |a Amirafzali, Iman |e verfasserin |4 aut | |
700 | 1 | |a Salami Khaneshan, Arezoo |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Mycopathologia |d 1975 |g 189(2024), 1 vom: 17. Jan., Seite 10 |w (DE-627)NLM000021288 |x 1573-0832 |7 nnns |
773 | 1 | 8 | |g volume:189 |g year:2024 |g number:1 |g day:17 |g month:01 |g pages:10 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11046-023-00808-z |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 189 |j 2024 |e 1 |b 17 |c 01 |h 10 |